Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000688844 | SCV000816469 | uncertain significance | Glycogen storage disease, type II | 2022-08-05 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 96 of the GAA protein (p.Lys96Glu). This variant is present in population databases (rs778816809, gnomAD 0.002%). This missense change has been observed in individual(s) with unexplained limb-girdle muscle weakness or elevated serum creatine kinase activity (PMID: 29149851). ClinVar contains an entry for this variant (Variation ID: 568474). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GAA protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001570772 | SCV001795119 | uncertain significance | not provided | 2019-04-29 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 29149851) |
Genome- |
RCV000688844 | SCV002027208 | uncertain significance | Glycogen storage disease, type II | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000688844 | SCV002091902 | uncertain significance | Glycogen storage disease, type II | 2020-02-18 | no assertion criteria provided | clinical testing |